Clinical Trial Update: Biomarker Modulation and the Inhibition of NKT1 Cells by Oral GRI-0621 in Patients With IPF [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for the oral agent GRI-0621 in idiopathic pulmonary fibrosis reports biomarker modulation and inhibition of NKT1 cells in treated …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• GRI-0621

Snippet

Sponsor: GRI Bio Operations, Inc. | Conditions: Idiopathic Pulmonary Fibrosis, IPF | Phase 2 | Status: COMPLETED